Write a Comment

Lapptj

Gilead initially studied tenofovir (Viread) alone for PEP and PreP, its mechanism of action appeared more promising for prevention. But tenofovir was replaced by the far more lucrative Truvada combo, which also had later patent life. Never saw any evidence that emtricitabine (Emtriva) added effectiveness to tenofovir alone, but it certainly helped Gilead's bottom line.

January 6, 2020 • Nyc